Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL759260 | 1.00 | DNM1 (0.40) | DNM1HRH3KDM5ADRD2DRD4 | |
| SCHEMBL757215 | 0.96 | DNM1 (0.45) | DNM1KDM5A | |
| SCHEMBL31273671 | 0.96 | DNM1 (0.45) | DNM1KDM5A | |
| SCHEMBL31273042 | 0.96 | DNM1 (0.45) | DNM1KDM5A | |
| SCHEMBL757613 | 0.96 | DNM1 (0.45) | DNM1KDM5A | |
| SCHEMBL516375 | 0.93 | DNM1 (0.50) | DNM1KDM5ACA12CA2CA9 | |
| SCHEMBL516239 | 0.93 | DNM1 (0.50) | DNM1KDM5ACA12CA2CA9 | |
| SCHEMBL755906 | 0.92 | LCK (0.36) | DNM1HRH3DRD2DRD4DRD3 | |
| SCHEMBL4180972 | 0.92 | LCK (0.36) | DNM1HRH3DRD2DRD4DRD3 | |
| SCHEMBL23921264 | 0.90 | DNM1 (0.48) | DNM1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2605069-B1 | RINSE LIQUID FOR LITHOGRAPHY AND METHOD FOR FORMING PATTERN USING SAME | MERCK PATENT GMBH (DE) | 2021-09-22 | — | — | EP | claimed |
| EP-3208659-A1 | COMPOSITION FOR RESIST PATTERNING AND METHOD FOR FORMING PATTERN USING SAME | AZ Electronic Materials (Luxembourg) S.à.r.l. (LU) | 2017-08-23 | — | — | EP | claimed |
| US-20170219927-A1 | COMPOSITION FOR RESIST PATTERNING AND METHOD FOR FORMING PATTERN USING SAME | AZ ELECTRIC MATERIALS (LUXEMBOURG) S.A.R.L. (LU) | 2017-08-03 | — | — | US | claimed |
| US-20130164694-A1 | RINSE SOLUTION FOR LITHOGRAPHY AND PATTERN FORMATION METHOD EMPLOYING THE SAME | AZ ELECTRONIC MATERIALS USA CORP. (US) | 2013-06-27 | — | — | US | claimed |
| EP-2605069-A1 | RINSE LIQUID FOR LITHOGRAPHY AND METHOD FOR FORMING PATTERN USING SAME | AZ Electronic Materials USA Corp. (US) | 2013-06-19 | — | — | EP | claimed |
| EP-4720172-A1 | SIDE-CHAIN FUNCTIONALIZED POLYNORBORNENES AS IONOMERS AND AS MEMBRANE MATERIALS FOR ALKALINE ELECTROLYSIS OF WATER, AND FUEL CELL | Forschungszentrum Jülich GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025242796-A1 | HYDROGENATED SIDE-CHAIN FUNCTIONALIZED POLYNORBORNENE-ANION EXCHANGE POLYMERS AS MEMBRANE MATERIALS FOR ALKALINE WATER ELECTROLYSIS AND FUEL CELLS | Forschungszentrum Jülich GmbH (DE) | 2025-11-27 | — | — | WO | disclosed |
| EP-3653584-B1 | DRAW SOLUTION WITH SWITCHABLE SALT ADDITIVE AND METHOD FOR DESALINATING AN AQUEOUS SOLUTION WITH THIS DRAW SOLUTION | UNIV KINGSTON (CA) | 2025-08-06 | — | — | EP | disclosed |
| US-12372875-B2 | Composition for resist pattern metallization process | NISSAN CHEMICAL CORPORATION (JP) | 2025-07-29 | — | — | US | disclosed |
| WO-2024245731-A1 | SIDE-CHAIN FUNCTIONALIZED POLYNORBORNENES AS IONOMERS AND AS MEMBRANE MATERIALS FOR ALKALINE ELECTROLYSIS OF WATER, AND FUEL CELL | Forschungszentrum Jülich GmbH (DE) | 2024-12-05 | — | — | WO | disclosed |
| US-20240036469-A1 | METHOD FOR MANUFACTURING THICKENED RESIST PATTERN, THICKENING SOLUTION, AND METHOD FOR MANUFACTURING PROCESSED SUBSTRATE | MERCK ELECTRONICS LTD. (JP) | 2024-02-01 | — | — | US | disclosed |
| US-11531269-B2 | Method for producing resist pattern coating composition with use of solvent replacement method | NISSAN CHEMICAL CORPORATION (JP) | 2022-12-20 | — | — | US | disclosed |
| US-7973030-B2 | Benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| WO-2011050469-A1 | SWITCHABLE HYDROPHILICITY SOLVENTS AND METHODS OF USE THEREOF | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2011-05-05 | — | — | WO | disclosed |
| US-7803792-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-5166029-A | Toner and developer compositions with charge enhancing additives | XEROX CORPORATION (US) | 1992-11-24 | — | — | US | disclosed |
| US-4179469-A | Preparation of amines | UOP INC. (US) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | DNM1 381/4885HRH3 2167/4885KDM5A 2878/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | DNM1 712/4885HRH3 404/4885KDM5A 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.